HIV-1 Drug-resistant Mutations and Related Risk Factors Among HIV-1-positive Individuals Experiencing Treatment Failure in Hebei Province, China

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2017 Jan 25

PMID 28114955

Citations 13

Authors

Xinli Lu

Hongru Zhao

Yuqi Zhang

Wei Wang

Cuiying Zhao

Yan Li

Lin Ma

Ze Cui

Suliang Chen

Affiliations

Soon will be listed here.

Abstract

Background: To understand HIV-1 drug resistance in 11 prefectures of Hebei Province, China, we implemented a cross-sectional HIV-1 molecular epidemiological survey.

Methods: Blood samples were collected from 122 newly diagnosed drug-naïve HIV-1-positive individuals and 229 antiretroviral therapy (ART)-failure individuals from 11 prefectures in Hebei Province, China. Patient demographic data were obtained via face-to-face interviews using a standardized questionnaire when blood samples were collected. Genotyping of HIV-1 drug resistance (DR) was implemented using an in-house assay.

Results: In this study, the overall prevalence of HIV-1 DR was 35.5%. The prevalence of HIV-1 DR in participants experiencing treatment failure and ART-naïve participants was 51.9 and 5.9%, respectively. Mutations in protease inhibitors, nucleoside reverse transcriptase inhibitors (NRTIs), and non-NRTI (NNRTIs), as well as dual and multiple mutations were extensively seen in participants experiencing treatment failure. The proportions of NNRTI mutations (χ = 9.689, p = 0.002) and dual mutations in NRTIs and NNRTIs (χ = 39.958, p < 0.001) in participants experiencing treatment failure were significantly higher than those in ART-naïve participants. The distributions of M184V/I and M41L mutations differed significantly among three main HIV-1 genotypes identified. Viral load, symptoms in the past 3 months, CD4 counts, transmission route, and the duration of ART were found to be associated with HIV-1 DR.

Conclusions: Our results suggest that new prevention and control strategies should be formulated according to the epidemic characteristics of HIV-1-resistant strains in Hebei Province, where antiretroviral drugs are widely used.

Citing Articles

Drug resistance mutations to integrase inhibitors, proteinase, and reverse transcriptase inhibitors in newly diagnosed HIV-1 infections in Hebei province, China, 2018-2022.

Lu X, Li Y, Liu M, Wang Y, An N, Sun D Front Cell Infect Microbiol. 2025; 15:1510916.

PMID: 40066069 PMC: 11891186. DOI: 10.3389/fcimb.2025.1510916.

Epidemic trend, genetic characteristics, and transmission networks of HIV-1 among treatment-naive men who have sex with men in Hebei province, China.

Lu X, Wang Y, Ma L, Liu M, Li Y, An N Front Microbiol. 2024; 15:1405565.

PMID: 39176274 PMC: 11339959. DOI: 10.3389/fmicb.2024.1405565.

Magnitude and Determinants of Virological Failure Among Patients >15 Years on Anti-Retroviral Therapy in Rural Lesotho Between 2015 and 2019 - A Retrospective Cohort Study.

Lejone T, Mahomed O HIV AIDS (Auckl). 2023; 15:611-620.

PMID: 37849794 PMC: 10577259. DOI: 10.2147/HIV.S424277.

Genetic characterization of HIV-1 viruses among cases with antiretroviral therapy failure in Suzhou City, China.

Dong Z, Xu Z, Zhou Y, Tian R, Zhou K, Wang D AIDS Res Ther. 2023; 20(1):41.

PMID: 37381002 PMC: 10303762. DOI: 10.1186/s12981-023-00540-0.

HIV-1 Drug Resistance Profiles of Low-Level Viremia Patients and Factors Associated With the Treatment Effect of ART-Treated Patients: A Cross-Sectional Study in Jiangsu, China.

Yuan D, Zhou Y, Shi L, Liu Y, Lu J, Chen J Front Public Health. 2022; 10:944990.

PMID: 35910928 PMC: 9330384. DOI: 10.3389/fpubh.2022.944990.

References

Arenas M . Genetic Consequences of Antiviral Therapy on HIV-1. Comput Math Methods Med. 2015; 2015:395826. PMC: 4478298. DOI: 10.1155/2015/395826. View

von Wyl V, Yerly S, Burgisser P, Klimkait T, Battegay M, Bernasconi E . Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis. 2009; 48(7):979-87. DOI: 10.1086/597352. View

Lu X, Zhao C, Wang W, Nie C, Zhang Y, Zhao H . HIV-1 genetic diversity and its distribution characteristics among newly diagnosed HIV-1 individuals in Hebei province, China. AIDS Res Ther. 2016; 13:3. PMC: 4719688. DOI: 10.1186/s12981-015-0087-2. View

Wu Z, Sullivan S, Wang Y, Rotheram-Borus M, Detels R . Evolution of China's response to HIV/AIDS. Lancet. 2007; 369(9562):679-90. PMC: 7137740. DOI: 10.1016/S0140-6736(07)60315-8. View

Li J, Li L, Li H, Zhuang D, Liu S, Liu Y . Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations. Chin Med J (Engl). 2009; 122(9):1081-6. View

Lu X, Kang X, Chen S, Zhao H, Liu Y, Zhao C . HIV-1 Genetic Diversity and Transmitted Drug Resistance Among Recently Infected Individuals at Men Who Have Sex with Men Sentinel Surveillance Points in Hebei Province, China. AIDS Res Hum Retroviruses. 2015; 31(10):1038-45. DOI: 10.1089/AID.2015.0160. View

Zhang F, Pan J, Yu L, Wen Y, Zhao Y . Current progress of China's free ART program. Cell Res. 2005; 15(11-12):877-82. DOI: 10.1038/sj.cr.7290362. View

Zeng Y . [Isolation of human immunodeficiency virus from AIDS patient]. Zhonghua Liu Xing Bing Xue Za Zhi. 1988; 9(3):135-7. View

Li H, Zhong M, Guo W, Zhuang D, Li L, Liu Y . Prevalence and mutation patterns of HIV drug resistance from 2010 to 2011 among ART-failure individuals in the Yunnan Province, China. PLoS One. 2013; 8(8):e72630. PMC: 3757030. DOI: 10.1371/journal.pone.0072630. View

10.

Yu E, Xie Q, Zhang K, Lu P, Chan L . HIV infection and AIDS in China, 1985 through 1994. Am J Public Health. 1996; 86(8):1116-22. PMC: 1380623. DOI: 10.2105/ajph.86.8_pt_1.1116. View

11.

Zhao S . [AIDS surveillance in Yunnan Province in China (1986-1990)]. Zhonghua Liu Xing Bing Xue Za Zhi. 1991; 12(2):72-4. View

12.

He X, Xing H, Ruan Y, Hong K, Cheng C, Hu Y . A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey. PLoS One. 2012; 7(10):e47289. PMC: 3466245. DOI: 10.1371/journal.pone.0047289. View

13.

Yuan Y, Xing H, Wang X, Liu C, Yang L, Zheng B . [The prevalence of HIV-1 drug resistance and associated factors in AIDS patients receiving HAART in Zhecheng county, Henan province]. Zhonghua Yu Fang Yi Xue Za Zhi. 2011; 45(7):619-24. View

14.

Lu L, Jia M, Ma Y, Yang L, Chen Z, Ho D . The changing face of HIV in China. Nature. 2008; 455(7213):609-11. DOI: 10.1038/455609a. View

15.

Li L, Sun G, Zhong P, Han J, Li T, Jia D . HIV-1 Thai B strain has spread out of former plasma donors into general population through sexual contact in Henan, China. J Med Virol. 2015; 88(4):614-21. DOI: 10.1002/jmv.24383. View

16.

Avila-Rios S, Garcia-Morales C, Tapia-Trejo D, Meza R, Nunez S, Parham L . HIV Drug Resistance Surveillance in Honduras after a Decade of Widespread Antiretroviral Therapy. PLoS One. 2015; 10(11):e0142604. PMC: 4641727. DOI: 10.1371/journal.pone.0142604. View

17.

Wang N, Wang L, Wu Z, Guo W, Sun X, Poundstone K . Estimating the number of people living with HIV/AIDS in China: 2003-09. Int J Epidemiol. 2010; 39 Suppl 2:ii21-8. PMC: 2992614. DOI: 10.1093/ije/dyq209. View

18.

Liu J, Wu Y, Yang W, Xue X, Sun G, Liu C . Population-based human immunodeficiency virus 1 drug resistance profiles among individuals who experienced virological failure to first-line antiretroviral therapy in Henan, China during 2010-2011. AIDS Res Ther. 2015; 12:22. PMC: 4483220. DOI: 10.1186/s12981-015-0062-y. View

19.

Zhang F, Dou Z, Ma Y, Zhao Y, Liu Z, Bulterys M . Five-year outcomes of the China National Free Antiretroviral Treatment Program. Ann Intern Med. 2009; 151(4):241-51, W-52. DOI: 10.7326/0003-4819-151-4-200908180-00006. View

20.

Zeng Y . [Serological screening of HIV antibody in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 1988; 9(3):138-40. View